{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '9.1.2 Leucovorin', 'Leucovorin (calcium folinate; e.g. Leucovorin 10mg/ml Pfizer) is administered intravenously', 'according to the respective package insert and local routine.', '9.1.2.1 Possible Adverse Effects of Leucovorin', 'Rare adverse effects related to Leucovorin are: Central nervous and/or gastrointestinal', 'disturbances, allergic reactions. Please refer to the respective SmPC for further details.', '9.1.3 5-Fluorouracil', '5-Fluorouracil (e.g. 5-FU; e.g. 5-FU 50mg/ml Medac) is administered intravenously as', 'described in section 10 (Therapy schema), according to the respective package insert and', 'local routine at the respective study site.', 'Fluorouracil (5-FU) must not be given in combination with brivudin, sorivudin and analogues.', 'Brivudin, sorivudin and analogues are potent inhibitors of the 5-FU-metabolising enzyme', 'dihydropyrimidine dehydrogenase (DPD). Fluorouracil (5-FU) must not be given to patients', 'homozygotic for dihydropyrimidine dehydrogenase [mutations] (DPD). Where applicable,', 'determination of DPD enzyme activity is indicated before starting treatment with 5-', 'fluorpyrimidines.', '9.1.3.1 Possible Adverse Effects of 5-Fluorouracil', 'Nausea/vomiting, diarrhea, mucositis, hand-foot-skin-reactions, disturbances in cardiac', 'function, skin alterations, alopecia, hematotoxicity. Please refer to the respective SmPC', '(Fachinformation) for further details.', '9.2 mFOLFOXIRI', 'See section above for details on Oxaliplatin (Section 9.1.1), Leucovorin (Section 9.1.2) and 5-', 'Fluorouracil (Section 9.1.3).', '9.2.1 Irinotecan', 'Irinotecan is in topoisomerase inhibitor and works by blocking topoisomerase 1 which results', 'in DNA damage and cell death. Irinotecan is administered intravenously according to the', 'respective package insert and local routine.', '9.2.1.1 Possible Adverse Effects of Irinotecan', 'Common side effects include diarrhea, vomiting, bone marrow suppression, alopecia,', 'shortness of breath, and fever. Other severe side effects include blood clots, colon', 'inflammation, and allergic reactions. Please refer to the respective SmPC for further details.', 'Confidential', 'Page 64 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '10 Administrative and Regulatory Details', '10.1 Regulatory and Ethical Compliance', 'This clinical trial was designed and shall be implemented and reported in accordance with the', 'protocol, the AMG (Arzneimittelgesetz), the ICH Harmonized Tripartite Guidelines for Good', 'Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC),', 'and with the ethical principles laid down in the Declaration of Helsinki.', 'Before recruitment into the clinical trial, each patient will be informed that participation in the', 'study is completely voluntary, and that he or she may withdraw his or her participation in the', 'trial at any time without any declaration of reasons. This will not lead to any disadvantage for', 'the respective patient. If the withdrawal is caused by an adverse drug event, the patient should', 'inform the Investigator about this fact.', '10.2 Registration and Request for Authorization of the Trial', 'According to GCP-V, the trial has to be submitted to and to be authorized/approved by the', 'competent authority (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, BfArM) and the', 'Ethics Committee(s) responsible for the trial. The respective local authorities will be informed', 'about the trial and the participation of individual trial sites.', 'The competent authority and the competent Ethics Committee will be informed on the course', 'of the study with respect to safety aspects to be announced as well as on the termination of', 'the trial and the trial results according to GCP-V.', '10.3 Ethics Committee', 'Prior to start of the trial the study protocol and all additionally relevant documents will be sent', 'by the Sponsor or designee to the competent Ethics Committee in order to receive the', \"committee's opinion. The trial is only allowed to start after a positive vote of the Ethics\", 'Committee has been received. During the course of the study the Sponsor or designee will', 'inform the Ethics Committee about all amendments to the study protocol as well as on all', 'SUSARs emerging from the trial according to GCP-V. In addition, the competent ethical', 'committee will receive a DSUR once a year.', 'All subsequent protocol amendments and amendments to the informed consent form will be', 'submitted to the competent Ethics Committee to obtain an updated vote before implementation', 'of the changes. Serious or unexpected adverse events occurring during the trial likely to affect', 'the safety of the subjects or the conduct of the trial will also be reported to the Ethics', 'Committee.', 'In addition, the competent Ethics Committee will be informed on the course of the study with', 'respect to the termination of the trial and the trial results.', 'Confidential', 'Page 65 of 79']\n\n###\n\n", "completion": "END"}